WATCH LIVE
timothy sykes logo
Kymera Therapeutics KYMR Stock Jumps On Pipeline Momentum Thumbnail
G Google News

Kymera Therapeutics KYMR Stock Jumps On Pipeline Momentum

JACK KELLOGG•UPDATED JUN. 25, 2026, 5:04 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Kymera Therapeutics Inc. stocks have been trading up by 18.4 percent following highly positive news driving strong investor optimism.

Key Takeaways

  • New KT-579 lupus preclinical data show disease‑modifying activity with biomarkers matching or beating approved therapies, backing Kymera’s IRF5 degradation strategy.
  • Sanofi’s first dosing of KT-485 in Phase 1 unlocked a $20M milestone for Kymera under a collaboration that could total up to $975M plus profit‑share and royalties.
  • Phase 1 KT-621 data in Japanese volunteers showed ≥98% STAT6 degradation and clean safety, enabling Japanese enrollment into global Phase 2b atopic dermatitis and asthma trials.
  • Biotech heavyweight Felix Baker has taken over as Kymera chairman while co‑founder Bruce Booth stays on the board, signaling continuity plus fresh strategic oversight.
  • Director Bruce Booth sold up to 478,198 shares on 2026/06/17 for about $45.3M but still indirectly controls roughly 4.1M shares, according to SEC filings.

Candlestick Chart

Live Update At 17:04:01 EDT: On Thursday, June 25, 2026 Kymera Therapeutics Inc. stock [NASDAQ: KYMR] is trending up by 18.4%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

KYMR has been on a tear. From 2026/06/01 to 2026/06/25, Kymera Therapeutics stock ripped from a close around $78 to $116.46, a gain of roughly 48% in just over three weeks. The move was not straight up; KYMR consolidated in the low‑80s to low‑90s before exploding through $100 and then sprinting to a 130.05 intraday high on 2026/06/25.

Intraday on the latest session, KYMR showed classic momentum behavior. After a gap up from about $100 to $121 at the open, the stock pushed into the mid‑120s, tagged 130.05, then cooled off into a tight consolidation between $115 and $118 into the close. That tells traders dip‑buyers were active and shorts struggled to push it back toward the morning lows.

More Breaking News

Under the hood, Kymera is still a classic clinical‑stage biotech story. Revenue over the last year sits near $39.2M, but the company runs heavy R&D, with a recent quarterly net loss of about $69.2M and EBITDA around -$67.2M. Kymera holds roughly $650.9M in cash and short‑term investments, a current ratio above 10, and very low debt. For traders, that balance sheet strength plus a rich price‑to‑sales ratio near 130 says the market is paying up for Kymera’s degrader pipeline, not today’s earnings.

Why Traders Are Watching KYMR Now

Traders are locked in on KYMR because the news flow lines up almost perfectly with the chart. Kymera Therapeutics has stacked a series of pipeline wins, governance moves, and partnership milestones that help explain why the stock has surged.

First, KT-579 for lupus is a big swing. Kymera reported new preclinical data showing this oral IRF5 degrader drove disease‑modifying activity in multiple lupus models, with biomarker reductions comparable or even superior to approved therapies. For traders, that reads like a de‑risking event in a tough autoimmune space. On top of that, Kymera already has a Phase 1 healthy volunteer trial underway, with data expected in 2H26 and a patient proof‑of‑concept trial likely to follow. That sets up a clear catalyst timeline, which is exactly what momentum traders want.

Second, the Sanofi collaboration around KT-485 gives KYMR external validation and real cash. Sanofi dosed the first participant in a Phase 1 trial of this second‑generation oral IRAK4 degrader for hidradenitis suppurativa, triggering a $20M milestone payment. The broader deal could be worth up to $975M in milestones plus U.S. profit‑share and ex‑U.S. royalties. For smaller biotechs like Kymera Therapeutics, big‑pharma‑run trials reduce execution risk and help explain why traders are willing to chase strength.

Third, KT-621, Kymera’s oral STAT6 degrader, continues to look clean. Phase 1 data in healthy Japanese adults showed rapid absorption, dose‑proportional exposure, ≥98% STAT6 degradation, and good tolerability, fully consistent with earlier studies. That cleared a key regulatory step to bring Japanese patients into global Phase 2b trials in atopic dermatitis and asthma, with readouts expected in 2027. The market’s modest premarket dip on that news looks more like “sell the news” than a real fundamental issue, and active traders are watching to see if price catches up to the clinical story.

Layer on top the governance shift: Felix Baker, a well‑known biotech deal‑maker, is now chairman of Kymera Therapeutics while co‑founder Bruce Booth remains on the board. That combination of a high‑conviction biotech name stepping up and founder continuity often reassures institutions and short‑term traders alike.

Conclusion

This is not trading advice, but it is clear why KYMR sits on so many watchlists right now. The stock is in a strong uptrend, riding a wave of positive news that touches every key angle: KT-579 showing promising lupus data with a 2H26 readout on deck, KT-485 advancing under Sanofi with a fresh $20M check, and KT-621 quietly marching toward 2027 Phase 2b data in large atopic dermatitis and asthma markets. Kymera Therapeutics keeps adding blocks to a multi‑asset degrader story, and the tape reflects that.

Traders do need to respect the other signals. Insider Form 4s show Bruce Booth sold up to 478,198 KYMR shares on 2026/06/17 for roughly $45.3M, even though he still controls about 4.1M shares. That kind of sale can create short‑term overhang and intraday fades, especially after a big run. Leadership changes, including Penny Carlson stepping in to run development operations while the COO retires to an advisory role, remind traders that execution risk is always present in a company scaling multiple global trials.

For active traders who live by patterns, catalysts, and risk management, KYMR is a classic “hot biotech” case study. Big moves, real news, and plenty of volatility. As Tim Sykes loves to say, “The market doesn’t owe you anything — it only rewards preparation and discipline.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. With Kymera Therapeutics, the traders who study the pipeline, track the catalysts, and cut losses fast will be the ones best positioned to take advantage of whatever this chart does next.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”